Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

NCT01068717 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
DRUG: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
DRUG: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
DRUG: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)

Sponsor

AstraZeneca